Sinaptica’s Breakthrough Device Could Slow Brain Atrophy In Alzheimer’s Patients – Study
Firm’s Is One Of Several FDA-Designated Breakthroughs Aiming To Outshine Drug Treatments
Executive Summary
In a pilot study building on previously published Phase 2 trial results, Sinaptica’s precision therapy, combining repetitive transcranial magnetic stimulation with EEG monitoring and artificial intelligence, showed macro- and micro-structural grey matter preservation and increased functional connectivity in Alzheimer’s patients versus a sham treatment arm.